未找到相关数据
A phase I multicenter study to assess the safety, tolerability, and immunogenicity of mRNA-4157 alone in patients with resected solid tumors and in combination with pembrolizumab in patients with unresectable solid tumors.
被引：109
作者：
Burris, Howard A.
Patel, Manish R.
Cho, Daniel C.
Clarke, Jeffrey Melson
Gutierrez, Martin
Zaks, Tal Z.
Frederick, Joshua
Hopson, Kristen
Mody, Kinjal
Binanti-Berube, Alverina
Robert-Tissot, Celine
Goldstein, Bree
Breton, Ben
Sun, Jing
Zhong, Shan
Pruitt, Scott K.
Keating, Karen
Meehan, Robert S.
Gainor, Justin F.
机构：
[1] Sarah Cannon Res Inst, Nashville, TN USA
[2] Florida Canc Specialists, Sarasota, FL USA
[3] NYU, Sch Med, New York, NY USA
[4] Duke Univ, Med Ctr, Durham, NC USA
[5] Hackensack Univ Med Ctr, Hackensack, NJ USA
[6] Moderna Tx, Cambridge, MA USA
[7] Merck & Co Inc, Kenilworth, NJ USA
[8] Massachusetts Gen Hosp, Boston, MA 02114 USA
关键词：
D O I：
10.1200/JCO.2019.37.15_suppl.2523
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2523
引用
收藏
页数：2
相关论文